|Videos|January 26, 2018
FDA Approval of Second Dosing Schedule of Nivolumab
Advertisement
Episodes in this series
Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.
The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.
Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.
For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5